Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug

References

• Arato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use on Schizophrenia (ZEUS) Study. Int Clin Psychopharmacol 2002; 17: 207–215
   PubMed Web of Science ®Google Scholar
• Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004; 1010: 81–86
   PubMed Web of Science ®Google Scholar
• Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979; 136: 317–320
   PubMed Web of Science ®Google Scholar
• Chinese Society of Psychiatry. 2001. The Chinese Classification and Diagnostic Criteria of Mental Disorders Version 3 (CDSM-3). Jinan: Chinese Society of Psychiatry.
   Google Scholar
• Chen YF. Chinese classification of mental disorders (CCMD-3): towards integration in international classification. Psychopathology 2002; 35: 171–175
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414–425
   PubMed Web of Science ®Google Scholar
• Davé M. Clozapine-related tardive dyskinesia. Biol Psychiatry 1994; 35: 886–887
   PubMed Web of Science ®Google Scholar
• de Leon J, Moral L, Camuňas C. Clozapine and jaw dyskinesia: a case report. J Clin Psychiatry 1991; 52: 494–495
   PubMed Web of Science ®Google Scholar
• Doepp S, Buddeberg C. Extrapyramidal symptoms following clozapine therapy: case report. Nervenarzt 1975; 46: 589–590
   PubMed Web of Science ®Google Scholar
• Ertugrul A, Demir B. Clozapine-induced tardive dyskinesia: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 633–635
   PubMed Web of Science ®Google Scholar
• Fehsel K, Loeffler S, Krieger K, Henning U, Agelink M, Kolb-Bachofen V, et al. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol 2005; 25: 419–426
   PubMed Web of Science ®Google Scholar
• Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000; 61: 10–14
   PubMed Web of Science ®Google Scholar
• Gafoor R, Brophy J. Three case reports of emergent dyskinesia with clozapine. Eur Psychiatry 2003; 18: 260–261
   PubMed Web of Science ®Google Scholar
• Huang JZ, Weng SW, Xie B, Yang XH, Shi SS, Xu YF. Clozapine and tardive dyskinesia: controlled study. Chin J Nerv Ment Dis 2000; 2: 113–114
   Google Scholar
• Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 1995; 52: 756–765
   PubMed Web of Science ®Google Scholar
• Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 1988; 8: 52–56
   PubMed Web of Science ®Google Scholar
• Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia?. J Clin Psychiatry 1993; 54: 327–330
   PubMed Web of Science ®Google Scholar
• Krabbendam L, van Harten PN, Picus I, Jolles J. Tardive dyskinesia is associated with impaired retrieval from long-term memory: the Curacao Extrapyramidal Syndrome Study IV. Schizophr Res 2000; 42: 41–46
   PubMed Web of Science ®Google Scholar
• Lidow MS, Goldman-Rakic PS. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 1997; 283: 939–946
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–510
   PubMed Web of Science ®Google Scholar
• Llorca PM, Chereau I, Bayle FJ, Lancon C. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 2002; 17: 129–138
   PubMed Web of Science ®Google Scholar
• Maytal G, Ostacher M, Stern TA. Aripiprazole-related tardive dyskinesia. CNS Spectr 2006; 11: 435–439
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Luchins DJ. Effect of clozapine in severe tardive dyskinesia: a case report. J Clin Psychopharmacol 1984; 4: 286–287
   PubMed Web of Science ®Google Scholar
• Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233–255
   PubMed Web of Science ®Google Scholar
• Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65: 500–508
   PubMed Web of Science ®Google Scholar
• Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005; 80: 33–43
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990; 54: 1755–1760
   PubMed Web of Science ®Google Scholar
• O'Dell SJ, La Hoste GJ, Widmark CB, Shapiro RM, Potkin SG, Marshall JF. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 1990; 6: 146–153
   PubMed Web of Science ®Google Scholar
• Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics: a retro- and prospective study of extrapyramidal side effects. Psychopharmacology 1996; 124: 188–196
   PubMed Web of Science ®Google Scholar
• Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP + -induced apoptosis. Eur J Neurosci 2003; 17: 1563–1570
   PubMed Web of Science ®Google Scholar
• Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60: 5–14
   PubMed Web of Science ®Google Scholar
• Simpson G, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology 1978; 56: 75–80
   PubMed Web of Science ®Google Scholar
• Waddington JL, O'Callaghan E, Larkin C, Kinsella A. Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia?. Brain Cogn 1993; 23: 56–70
   PubMed Web of Science ®Google Scholar
• Wegner JT, Kane JM, Weinhold P, Woerner M, Kinon B, Lieberman J. Cognitive impairment in tardive dyskinesia. Psychiatry Res 1985; 16: 331–337
   PubMed Web of Science ®Google Scholar
• Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK. Induction of metabolism-dependent and independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000; 58: 207–216
   PubMed Web of Science ®Google Scholar
• Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992; 18: 701–715
   PubMed Web of Science ®Google Scholar
• Yoon JY, Oh DY, Choi JH. Prevalence of tarcive dyskinesia in inpatients using antipsycotics. Korean J Psychopharmacol 2004; 15: 305–311
   Google Scholar